Qlucore Launches First CE-Marked Diagnostic Test for Pediatric Leukemia

Qlucore has launched the first CE-marked RNA-seq based diagnostic test for pediatric leukemia under Europe’s IVDR framework. Now available for clinical use, this test enhances diagnostic accuracy, enabling more personalized treatment and better outcomes for children with this common cancer.

Introducing Qlucore Diagnostics for BCP-ALL

This unique and new test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. It includes both gene expression subtype classification of B-cell leukemias and gene fusion analysis support. Start using it today and get a regulatory approved test that benefits from:

•    Machine learning based subtype classification with enhanced subtype coverage. Reduces the risk of escalated and expensive treatments. An additional 7% of samples are subtyped using gene expression profiles, enabling detection of DUX4-rearranged and ETV6::RUNX1-like subtypes.

•    Simplified lab work. Utilizing standard wetlab and standard kits. Combines gene expression-based subtyping and gene fusions in one clinical report.

•    Robustness. Utilizes up to three different gene fusion callers for improved coverage. Gene fusions are presented in Tiers including all detected fusions.

•    Cost-effective. Can replace FISH tests with significant cost savings.

•    Future proof. Whole Transcriptome Sequencing (WTS) allows all fusions to be clinically annotated, with future updates in software rather than in lab workflows.

By integrating advanced genetic analysis with user-friendly software, we are empowering diagnostic laboratories and clinicians to make informed decisions that enhance patient care. Join our webinar to learn more. For a complete description of the intended use, visit qlucore.com.

Contact us for an initial consultation and evaluation.

Upcoming webinar: 12th of March, 11:00 - 11:20 (CET): Qlucore Diagnostics BCP-ALL